Dacomitinib
Dacomitinib (PF-00299804) is a potent, orally active, and highly selective small-molecule inhibitor targeting the HER family tyrosine kinases, with IC50 values of 6 nM (EGFR), 45.7 nM (ERBB2), and 73.7 nM (ERBB4) . It is widely used in preclinical research to investigate oncogenic signaling in vitro and has demonstrated antitumor efficacy in various in vivo cancer models.
Product Specifications
CAS Number
1110813-31-4
Product Name Alternative
Inhibit, EGFR, Epidermal growth factor receptor, ErbB-1, Inhibitor, HER1, HER2/ErbB2, Dacomitinib, Apoptosis, PF299804, PF-299804, PF299, PF-299, PF 299, PF 299804, PF00299804, PF-00299804, PF 00299804
Field of Research
Cardiovascular Research, Cell Biology, Pharmacology & Drug Discovery, Signal Transduction
Purity
99.34% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.26 mM) ; DMSO:30 mg/mL (63.84 mM)
Smiles
COc1cc2ncnc (Nc3ccc (F) c (Cl) c3) c2cc1NC (=O) \C=C\CN1CCCCC1
Molecular Formula
C24H25ClFN5O2
Molecular Weight
469.94
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
